Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06649513

Long-term Ophthalmic Outcomes in Ex-premature Infants

There is limited knowledge on ophthalmological outcomes in the adult population that was born prematurely. This study aims to evaluate the ophthalmic outcomes of ex-premature infants that have reached adolescence or adulthood.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Every year, around 18.000 children in the Netherlands are born prematurely, which means that they were born before 37 weeks gestational age. The WHO defines three different categories of prematurity: moderate to late preterm (32-37 weeks), very preterm (<32-28 weeks), and extremely preterm (<28 weeks). Preterm birth is associated with numerous health problems, which can have both short-term and long-term consequences on the development of the child. A relatively rare complication of (very or extreme) preterm birth is lifelong visual impairment or blindness due to retinal detachment as a result of prematurity retinopathy (ROP). ROP is a vasoproliferative condition that affects the vessels in the retina. An inventory study shows that 305 children were diagnosed with ROP in the Netherlands in 2017. The majority of these children experienced spontaneous regression of the condition, but 13% of cases required treatment to prevent retinal detachment. In the long-term, ROP predisposes for ocular conditions such as visual field abnormalities, refractive error, strabismus, amblyopia, glaucoma and retinal detachment. However, research also indicates that prematurity, regardless of ROP diagnosis, can also be associated with adverse ophthalmological outcomes such as refractive error, strabismus, amblyopia and cerebral visual impairment (CVI). Although there are various publications on the ophthalmological outcomes of ROP and prematurity at school-age, less is known about these outcomes in the adult population. This study aims to investigate the anatomy and functionality of the eye in ex-premature infants who were born between 1991 and 2006. In addition, the differences in outcomes between ex-premature infants with and without ROP, and the differences in outcomes between treated and spontaneously regressed ROP, will be studied.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects eligible for ROP screening, and admitted to Erasmus MC between 1991 and 2007.

Exclusion criteria

  • Subjects born after 2008,
  • Subject has passed away before the start of the study
  • Subject resides outside of the Netherlands
  • Subject has a physical or mental disability that makes it impossible to participate in a routine eye exam, or has a disability that classifies the subject as an incapacitated adult.

Treatment and study plan

eye drops (Tropicamid)

Diagnostic Test

Mydriatic + cycloplegic eye drops are given to measure refractive error and to image the full retina.

Primary outcomes

  1. Visual acuity

    Time frame: The primary outcome measure will be assessed at one single visit to Erasmus MC. This one-off measurement will not be repeated, nor is there a specific time-frame for this measurement.

    Measured with ETDRS chart. Expressed in Logarithm of the Minimum Angle of Resolution (LogMAR)

Secondary outcomes

  1. Biometric, refractive, fundus and Optical coherence tomography (OCT) data.

    Time frame: The secondary outcome measures will be assessed at one single visit to Erasmus MC. These one-off measurements will not be repeated, nor are there a specific time-frames for these measurements.

    • Refraction (spherical equivalent) in dioptre (D) measured with an automatic refractometer.
    • Optical biometry measurements (axial eye length in millimeters, lens thickness in millimeters, anterior chamber depth in millimeters) measured with an optical biometer.
    • Intra-ocular pressure (IOP) in millimeter in mercury (mmHg) measured with a non-contact or contact tonometer.
    • Visual field abnormalities measured with a Humphrey Field Analyzer (HFA), expressed as Visual Field Index (VFI), Mean Deviation (MD) and Pattern Standard Deviation (PSD) in decibels (dB).
    • Macula thickness in micrometers (µm) measured on Optical coherence tomography (OCT) images.
    • Any anatomical abnormalities of the retina and choroid seen on OCT of fundus images.
    • Presence of ophthalmological diagnoses such as amblyopia or strabismus.
    • Relevant (ophthalmological) medical history/ophthalmological diagnosis in the past.
    • Self-reported health, educational level, screen time and activity level (questionnaire).

Study contacts

Contact information is provided by the study sponsor or research team.

Angela Arends-Tjiam, Dr

CONTACT

[email protected]

+31653616960

Lizanne Derks, BSc

CONTACT

[email protected]

+31653901136

Sponsors and collaborators

Lead sponsor

Erasmus Medical Center

Other

Registry information

Acronym: LTOO-XP

Important dates

Study start
2024
Primary completion
2029
Study completion
2030
First posted
Oct 18, 2024
Registry last updated
Oct 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.